Epoetin beta and methoxy polyethylene glycol and Xarelto

• Generic Name: epoetin beta-methoxy polyethylene glycol
• Dosage Forms: n.a.
• Other Brand Names: Mircera

Epoetin beta and methoxy polyethylene glycol is a combination medicine used to treat anemia (lack of red blood cells) and to reduce the need for blood cell transfusions.

Epoetin beta and methoxy polyethylene glycol is used to treat anemia caused by chronic kidney disease in adults, or in children at least 5 years old who are on hemodialysis.

epoetin beta and methoxy polyethylene glycol is not for treating anemia caused by cancer chemotherapy. Epoetin beta and methoxy polyethylene glycol may increase tumor growth or decrease survival time in people with certain types of cancer.

Epoetin beta and methoxy polyethylene glycol should not be used to take the place of an emergency blood cell transfusion.

Epoetin beta and methoxy polyethylene glycol may also be used for purposes not listed in this medication guide.

• Generic Name: rivaroxaban
• Dosage Forms: tablet, film coated
• Other Brand Names: Xarelto, Xarelto Starter Pack

Xarelto (rivaroxaban) blocks the activity of certain clotting substances in the blood.

Xarelto is used to prevent or treat a type of blood clot called deep vein thrombosis (DVT), which can lead to blood clots in the lungs (pulmonary embolism). A DVT can occur after knee or hip replacement surgery, and during or after a stay in the hospital when you cannot move around as much as normal.

Xarelto is sometimes used to lower your risk of a DVT or PE coming back after you have received treatment for blood clots for at least 6 months.

Xarelto is used in people with atrial fibrillation (a heart rhythm disorder) to lower the risk of stroke caused by a blood clot.

Xarelto is used to help prevent blood clots in certain people hospitalized for an acute illness who are at risk of getting blood clots and who do not have a high risk of bleeding.

Xarelto is also given together with aspirin to lower the risk of stroke, heart attack, or other serious heart problems in people with coronary artery disease (decreased blood flow to the heart) or peripheral artery disease (decreased blood flow to the legs).